Novartis and Wockhardt appear to be crossing horns with each other at the Delhi High Court as well as the IPAB regarding the popular anti-diabetes drug vildagliptin recently. The proceedings before the High Court was an application for injunction filed by Novartis while the IPAB was hearing a revocation petition filed by Wockhardt. The dispute arose as a result of the permission granted to Wokhardt by the drug regulator to manufacture and sell the drug in May 2013. At the...
↧